Setterwalls has assisted Isofol when entering into a license agreement with Paladin

Isofol has entered into a license agreement for Paladin Labs Inc. to commercialize Isofol’s proprietary drug candidate arfolitixorin in Canada. Isofol may in accordance with the agreement receive up to $US 23.05 million plus double-digit royalty.

Setterwalls advised Isofol Medical AB (publ) when entering into a definitive license agreement with Endo Ventures Limited, a subsidiary of Endo International plc, for the registration and commercialization of Isofol’s proprietary drug candidate arfolitixorin on an exclusive basis in Canada. With the consent of Isofol, Endo Ventures Limited has designated Paladin Labs Inc., an operating company of Endo, to be responsible for seeking regulatory approval for arfolitixorin in Canada and after receipt of such approval, to be responsible for the commercialization of arfolitixorin in Canada, including distribution, marketing, medical affairs, pricing and reimbursement activities. Isofol may receive up to $US 23.05 million (SEK 205 million) as upfront, development, regulatory and sales-based milestone payments. In addition, Isofol will receive tiered royalties on net sales in solid double-digit figures.

Isofol is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol is traded on the Nasdaq First North Premier Growth Market.

Paladin, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing and sales organization that has helped it evolve into one of Canada’s leading specialty pharmaceutical companies. Endo Ventures Limited and Paladin are operating companies of Endo International plc.